



Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting

June 22, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 22, 2020--Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held online, June 22-24, 2020.

These abstract showcases data from [ImmunID NeXT](#), the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunID NeXT Platform® can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Following are details and links to the scientific posters that will be presented at the online meeting.

Abstract Number, Session Category and Session Title	Title & Presenter	Date	Location
2085 / 2 Bioinformatics and Systems Biology Machine Learning	Precision neoantigen discovery using a pan-allelic machine learning model for enabling the development of composite biomarkers and personalized immunotherapy Presenter: Datta Mellacheruvu	June 22, 2020	Online
1989 / 26 Clinical Research Circulating Markers 2	Enhanced whole exome profiling of tumor circulating cell-free DNA enables sensitive assessment of tumor mutations Presenters: Mengyao Tan and Simo V. Zhang	June 22, 2020	Online
1334 / 29 Molecular and Cellular Biology/Genetics Genomic Profiling of Tumors 2	A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome Presenter: Robert Power	June 22, 2020	Online
2512 / 28 Molecular and Cellular Biology/Genetics Genomic Profiling of Tumors 3	Pan-cancer characterization of the tumor and immune microenvironment facilitates identification of cancer-specific biological signatures Presenter: Sean M. Boyle	June 22, 2020	Online
4430 / 25 Bioinformatics and Systems Biology Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging	Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome Presenter: Eric Levy	June 22, 2020	Online
4278 / 2 Clinical Research Predictive Biomarkers for Treatment Efficacy 3	A composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients Presenter: Charles Abbott	June 22, 2020	Online
6678 / 24 Immunology Immune Response to Therapies 2	Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy Presenter: Rachel Marty Pyke	June 22, 2020	Online
852 / 2 Bioinformatics and Systems Biology Machine Learning and Artificial Intelligence for Omics, Imaging, and Diagnostics	Improved tumor-only somatic variant calling using a gradient boosted machine learning algorithm Presenter: Nick Phillips	June 22, 2020	Online

About Personalis

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® [ImmunID NeXT Platform](#)® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis® [Clinical Laboratory](#) is GxP-aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](#)).

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis' filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200622005219/en/): <https://www.businesswire.com/news/home/20200622005219/en/>

Investor Relations Contact:

Caroline Corner

investors@personalis.com

415-202-5678

Media Contact:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.